Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy

Mostrar otras versiones (1)

Prognosis for patients suffering from malignant glioma has not substantially improved. Specific immunotherapy as a novel treatment concept critically depends on target antigens, which are highly overexpressed in the majority of gliomas, but the number of such antigens is still very limited. SOX2 was...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitz, M, Temme, A, Senner, V, Ebner, R, Schwind, S, Stevanovic, S, Wehner, R, Schackert, G, Schackert, H K, Fussel, M, Bachmann, M, Rieber, E P, Weigle, B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Genetics and Genomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360145/
https://www.ncbi.nlm.nih.gov/pubmed/17375044
http://dx.doi.org/10.1038/sj.bjc.6603696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360145/
https://www.ncbi.nlm.nih.gov/pubmed/17375044
http://dx.doi.org/10.1038/sj.bjc.6603696

Ejemplares similares